Sign In
Buy ABMD
$381.02
+0 (+0%)
At Close: Mar 20, 2023
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
02:18pm, Tuesday, 15'th Mar 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Got $5,000? 3 Growth Stocks to Buy That Could Double Your Money
10:45am, Saturday, 12'th Mar 2022
They have a whole lot going right, and little in the way of obstacles.
Is Abiomed (ABMD) A Great Investment to Take?
02:10pm, Monday, 07'th Mar 2022 Insider Monkey
Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Riding The Stock Waves: Update On The Medical Devices Sector
08:00am, Monday, 21'st Feb 2022
Riding The Stock Waves: Update On The Medical Devices Sector
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
12:19pm, Friday, 11'th Feb 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference | MarketScreener
09:07pm, Tuesday, 08'th Feb 2022 MarketScreener
Abiomed, Inc. , a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at… | February 8, 2022
Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript
07:35pm, Thursday, 03'rd Feb 2022
Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript
Abiomed, Inc. 2022 Q3 - Results - Earnings Call Presentation
04:59pm, Thursday, 03'rd Feb 2022 Seeking AlphaAbiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance
02:35pm, Thursday, 03'rd Feb 2022
Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.
Abiomed Non-GAAP EPS of $1.13 beats by $0.16, revenue of $261.18M beats by $9.71M
12:10pm, Thursday, 03'rd Feb 2022 Seeking Alpha
Abiomed press release (ABMD): Q3 Non-GAAP EPS of $1.13 beats by $0.16.Revenue of $261.18M (+12.7% Y/Y) beats by $9.71M.The company is increasing the lower end of its fiscal year
Abiomed (ABMD) Q3 Earnings and Revenues Top Estimates
09:59am, Thursday, 03'rd Feb 2022
Abiomed (ABMD) delivered earnings and revenue surprises of 15.31% and 3.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Abiomed (ABMD) Could Beat Earnings Estimates Again
01:50pm, Thursday, 20'th Jan 2022
Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abiomed (ABMD) Reports Positive Data Backing preCARDIA System
01:05pm, Wednesday, 19'th Jan 2022
Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
07:00am, Friday, 14'th Jan 2022
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
01:07pm, Wednesday, 12'th Jan 2022
Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.
